

(12) PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. AU 199729962 B2
(10) Patent No. 717628

- (54) Title
Feline vaccines containing chlamydia psittaci and method for making the same
- (51)⁷ International Patent Classification(s)
A61K 039/118
- (21) Application No: **199729962** (22) Application Date: **1997.04.21**
- (87) WIPO No: **WO97/41889**
- (30) Priority Data
- | | | |
|------------------|-------------------|--------------|
| (31) Number | (32) Date | (33) Country |
| 08/643673 | 1996.05.06 | US |
- (43) Publication Date : **1997.11.26**
(43) Publication Journal Date : **1998.02.05**
(44) Accepted Journal Date : **2000.03.30**
- (71) Applicant(s)
Bayer Corporation; Bayer Aktiengesellschaft
- (72) Inventor(s)
Rebecca A. Atherton; Norbert Schmeer; Jean A. Hallstrom; Jennifer K. Lane; Kristina J. Hennessy
- (74) Agent/Attorney
DAVIES COLLISON CAVE,GPO Box 3876,SYDNEY NSW 2001
- (56) Related Art
US 5242686
VACCINE, VOL. (13)8, 1995, PP 715-723




CT)

<p>(51) International Patent Classification ⁶ : A61K 39/118</p>	<p>A1</p>	<p>(11) International Publication Number: WO 97/41889 (43) International Publication Date: 13 November 1997 (13.11.97)</p>
<p>(21) International Application Number: PCT/US97/07514 (22) International Filing Date: 21 April 1997 (21.04.97) (30) Priority Data: 08/643,673 6 May 1996 (06.05.96) US (71) Applicants: BAYER CORPORATION [US/US]; One Mellon Center, Pittsburgh, PA 15219 (US); BAYER AKTIENGESELLSCHAFT [DE/DE]; D-51368 Leverkusen (DE). (72) Inventors: ATHERTON, Rebecca, A.; 6208 Albervan, Shawnee, KS 66216 (US). SCHMEER, Norbert; Brucherkotten 1, D-42770 Haan (DE). HALLSTROM, Jean, A.; 6636 Hardy, Merriam, KS 66202 (US). LANE, Jennifer, K.; 5804 Haskins, Shawnee, KS 66216 (US). HENNESSY, Kristina, J.; 5215 N.W. Bluff Drive, Parkville, MO 64152 (US). (74) Agent: AKORLI, Godfried, R.; Bayer Corporation, 100 Bayer Road, Pittsburgh, PA 15205 (US).</p>		<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). <i>100 Bayer Road Pittsburgh PA 15205 Published United States of America With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>

see
6/1/0
3



(54) Title: FELINE VACCINES CONTAINING CHLAMYDIA PSITTACI AND METHOD FOR MAKING THE SAME



(57) Abstract
 The present invention relates to feline vaccines comprising inactivated a non reactive Chlamydia psittaci for prevention and treatment of chlamydia diseases in cats.

**FELINE VACCINES CONTAINING CHLAMYDIA
PSITTACI AND METHOD FOR MAKING THE SAME**

BACKGROUND OF THE INVENTION

5 Feline chlamydiosis is a common conjunctival and respiratory
disease of cats known as feline pneumonitis (FPn). This highly
contagious disease is characterized by sneezing and coughing and is
accompanied by mucopurulent ocular and nasal discharges. All age
groups of cats are susceptible and, although mortality is not great,
10 infected kittens and older cats may become severely debilitated.
Because of its extreme infectivity, feline chlamydiosis constitutes a major
problem in pet hospitals, clinics and catteries. There is some thought
that persistent genital tract infection by Chlamydia psittaci is a cause of
reproductive failure in catteries.

15 Vaccination studies with modified-live compositions of Chlamydia
psittaci have produced conflicting results. Cello (Am. J. Vet. Med. Assoc.
158:932-938, 1971) indicated that such vaccines demonstrated no
significant protection of cats. Shewen, et al. (Can. J. Comp. Vet. Res.
44:244-251, 1980) indicated partial protection while McKercher (Am. J.
20 Vet. Res. 13:557-561, 1952) and others indicated almost complete
protection by such vaccines. However, because the vaccinated cats are
receiving live Chlamydia psittaci, some vaccine organisms can shed to
other cats and reversion has been proposed to occur.

25 Studies with inactivated chlamydia vaccines have produced mixed
results and unacceptable local and systemic reactions in vaccinated cats.
Comparative challenge studies conducted with four inactivated vaccine
preparations and a commercial modified-live vaccine demonstrated that
the inactivated preparations conferred virtually no protection against
chlamydia infection in cats (Shewen et al, Can. J. Comp. Med. 44:244-
30 251, 1980). An inactivated Chlamydia psittaci vaccine has been

described by Chu et al. (U.S. Pat. No. 5,242,686). However, this vaccine is not purified and causes unacceptable local reactions when administered to cats (COMPENDIUM).

5 With the knowledge that modified-live chlamydia vaccines can shed to other animals, can recombine with field strains of Chlamydia psittaci and can revert to virulence, and the knowledge that currently-marketed inactivated chlamydia vaccines are either ineffective or cause unacceptable local reactions, there is a need for effective, non-reactive chlamydia vaccines. It is an object of the present invention to provide an
10 inactivated feline chlamydia vaccine composition having high immunogenicity without having a high antigenic mass. It is another object of this invention to provide a simple process for producing a suitable purified Chlamydia psittaci for production of a non-reactive, effective vaccine as a monovalent preparation or in a combination with
15 other feline antigens.

The present invention discloses an inactivated, immunogenically effective Chlamydia psittaci which is incorporated into chlamydia vaccines in minute quantities (low antigen load or low antigen mass) and which is purified away from the cells in which it is grown so as to produce a
20 vaccine which, when administered to cats is non-reactive but highly effective. In such vaccine the immunogenically effective, low antigen mass, purified Chlamydia psittaci is combined with effective amounts of an adjuvant and a pharmaceutically acceptable carrier or diluent therefor. The purification process for production of the Chlamydia psittaci
25 incorporates several steps which include use of the yolk sac membrane, washed free of yolk material, as seed to inoculate a mammalian cell line such as the Buffalo Green Monkey (BGM) cell line

and, after completion of the cell destruction by the chlamydia (cytopathic effect or CPE), removing the cells and cellular
30 debris from the vaccine preparation prior to inactivation. One of the



major requirements of this invention is that the cell line used for growth of the Chlamydia psittaci be destroyed by the organism within 7 days of infection with the Chlamydia psittaci (demonstrate at least 80% CPE within 7 days of infection with the chlamydia).

5 BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a graph of a group summary of clinical scores (mean score/day which is further reported in Table 1: showing that minute quantities of Chlamydia psittacci (less than 50µg/dose), when made into a vaccine, protected as well as large amounts of Chlamydia psittaci (50-
10 1000µg/mL as noted by Chu et al.).


DETAILED DESCRIPTION OF THE INVENTION

The present invention provides a vaccine composition comprising a minute quantity of a purified, inactivated, immunogenically effective amount of Chlamydia psittaci in combination with an effective amount of
15 an adjuvant; and a pharmaceutically acceptable carrier or diluent therefor which may be combined with other feline antigens. When administered to cats, the vaccine is non-reactive but highly effective.


As used herein, the term "immunogenically effective amount" refers to the ability of the Chlamydia psittaci in the vaccine to protect cats
20 from infection with Chlamydia psittaci after they have been vaccinated. The term "minute quantity" refers to the amount of Chlamydia psittaci added to the vaccine being less than 50µg/dose. The term "purified" refers to processes which eliminate the presence of egg yolk material in the final vaccine. These processes include but are not limited to
25 inoculating the tissue culture with egg yolk sac membrane which has been washed free of egg yolk material with saline, ground and resuspended in phosphate buffered saline, using a cell line which is destroyed by the Chlamydia psittaci and removing the cells and cellular debris prior to inactivating the Chlamydia psittaci.

Thus, the present provides an inactivated, immunogenically effective Chlamydia psittaci vaccine which does not produce local systemic adverse reactions containing less than 50 μg /dose of Chlamydia psittaci.

10



15



20

25



The present invention also includes a process for preparing a vaccine composition against chlamydia infections comprising culturing Chlamydia psittaci in egg yolk sac, harvesting egg yolk sac membrane from said egg yolk sac and freezing it as a master seed, culturing said master seed or passages of said master seed in a highly susceptible cell line growing on a surface until at least 80% of the cell line is destroyed by the Chlamydia psittaci, harvesting the destroyed susceptible cell line and media containing the Chlamydia psittaci accompanying said cell line, removing the destroyed cell line from the Chlamydia psittaci, inactivating the Chlamydia psittaci and mixing the inactivated Chlamydia psittaci with an adjuvant and physiologically acceptable carrier.

Chlamydia psittaci has a development cycle with distinct reproductive (reticulate bodies) and infectious (elementary bodies) forms. When grown in the cell lines most commonly used for growth of Chlamydia (e.g. Dog Kidney cells, McCoy cells and CRFK cells) this organism does not produce a complete cytopathic effect on the cell sheet. This makes optimal time of harvest difficult to determine in a production setting. It also produces Chlamydia organisms with low immunogenicity such that they need to be multiply harvested from the cells or highly concentrated after harvest. In some cases (described in U.S. Patent No. 5,242,686) they must be inactivated in the subculture. These procedures result in a vaccine which has high antigen load (high antigen mass containing 50 to 1000 µg/dose) and which is reactive to cats post vaccination. Infection of cells, such as the Buffalo Green Monkey cell line, which are highly susceptible to infection with Chlamydia psittaci organisms, results in complete destruction of the cell sheet at which time the number of infectious organisms in the culture is very high. These organisms can be easily purified away from the cells and cellular debris by filtration, centrifugation or ultrafiltration and a minute quantity of the harvested purified Chlamydia psittaci (<50 µg/dose) is

immunogenically effective when formulated into a vaccine containing an adjuvant and an acceptable pharmaceutical carrier.

According to the invention, a chlamydia isolate such as the Cello strain of Chlamydia psittaci was first propagated in the yolk sac
5 membrane of embryonated chicken eggs. The Chlamydia psittaci isolate was inoculated into the yolk sac of embryonated chicken eggs and incubated at 37° C for 5-10 days. The eggs were candled daily starting at day 5 to determine viability. On the day that 25% of the eggs had died, the yolk sac membranes of the still-viable eggs were harvested,
10 washed with phosphate buffered saline to remove excess egg yolk protein material and aseptically blended, resuspending the blended membrane in phosphate buffered saline. One milliliter aliquots of this blended and resuspended seed material were stored frozen at -70° C. Up to 5 passages of this seed is made using the same procedure to
15 prepare the production seed useful for inoculating tissue culture cells.

Production of the Chlamydia psittaci vaccine antigen is accomplished by first preparing the tissue cell culture. Buffalo Green Monkey cells were grown in Dulbecco's MEM with high glucose (DMEM/H), 5% fetal bovine serum, 10mM HERPES buffer and neomycin.
20 When the cells were confluent they were infected with Chlamydia psittaci in DMEM/H with neomycin. The Chlamydia psittaci was adsorbed onto the cells with a low volume of media and then more DMEM/H media was added. The infected cells were incubated at 37° C for 5 to 7 days. Normally, by day 6 post-infection 90-100% of the cell sheet was
25 destroyed. At this point the Chlamydia psittaci was harvested (harvest fluids) by swirling the vessels to remove any remaining cells. The cells and cell debris were removed from the harvest fluids by 5 μ filtration or by centrifugation. Then the purified harvest fluids were inactivated. Inactivating agents include but are not limited to binary ethylenimine,
30 formalin, thimerosal and betapropiolactone. The pH was adjusted to

neutral and the purified harvest fluids were adjusted to an immunogenically effective amount for formulation with adjuvant by dilution in phosphate buffered saline. The immunogenically effective amount of Chlamydia psittaci was usually less than 50µg/dose and preferably less than 10µg/dose. Any adjuvant may be used. Non-limiting examples of adjuvants used in the present invention are polymers and co-polymers, acrylic acid polymers and co-polymers, polyacrylic acid such as Carbopol®, surfactants such as hexadecylamine, saponin, Quil A, aluminum hydroxide, aluminum phosphate, peptides such as muramyl dipeptide, oil emulsions, immunomodulators such as interleukins and interferons, interferon inducers, ethylene maleic anhydride copolymers such as EMA-31, NEOCRYL A640 and POLYGEN® (supplied by MVP Laboratories). Mixtures of any of the above adjuvants or adjuvant systems can also be used.

It has been discovered that adjuvants described above will act in effective amounts between 0.01% and 50% v/v of the total vaccine dose. Preferably, the concentration of adjuvant will be adjusted between 1% and 15%. More preferably, POLYGEN® is used at concentrations between 1% and 5% and Carbopol® is used at concentrations between 0.1% and 0.5%.

The vaccine composition of the present invention also comprises a pharmaceutically acceptable carrier or diluent and may include additional feline antigens such as antigens for feline rhinotracheitis, feline leukemia, feline calicivirus and feline panleukopenia, feline immunodeficiency virus, feline infectious peritonitis, Toxoplasma gondii and rabies.

TABLE 1 GROUP SUMMARY OF CLINICAL SCORES -- MEAN SCORE/DAY

Day	Control Group	25 μ L Antigen Mass	50 μ L Antigen Mass	100 μ L Antigen Mass
-3	0.00	0.00	0.00	0.00
1	0.05	0.00	0.00	0.05
5	2.63	0.78	1.00	0.85
9	3.38	0.88	0.75	0.63
13	3.60	0.93	0.63	0.58
17	3.23	0.90	1.00	0.73
21	3.76	0.68	0.98	0.93
25	3.15	0.20	0.65	0.60
Average of Days 5-28	3.29	0.73	0.83	0.72

Table 2 demonstrates that a multicomponent vaccine containing inactivated Feline Rhinotracheitis, Feline Calicivirus, Feline Panleukopenia virus, Feline Leukemia virus and Feline Chlamydia psittaci prepared according to this invention is efficacious.

TABLE 2 RESULTS OF EFFICACY TESTING OF 5-WAY FELINE VACCINE CONTAINING FELINE CHLAMYDIA PSITTACI, FELINE RHINOTRACHEITIS, FELINE LEUKEMIA, FELINE CALICIVIRUS AND FELINE PANLEUKOPENIA VIRUS

	CHALLENGE ANTIGEN	TITER RESPONSE NO. >1:8/TOTAL	PROTECTION
5	FELINE PANLEUKOPENIA SC IM CONT	4/4 4/4 0/4	100% 100% 0%
10	FELINE LEUKEMIA SC IM CONT	NA NA NA	80% 90% 22%
15	FELINE SC RHINOTRACHEITIS IM CONT	NA NA NA	EXCELLENT "T" = 34 VACC C.M. = 9.7 CONT. C.M. = 49.3 EXCELLENT "T" = 34 VACC C.M. = 8.3 CONT. C.M. = 49.3 NONE
20	FELINE CALICIVIRUS SC IM CONT	NA NA NA	EXCELLENT "T" = 34 VACC C.M. = 9.0 CONT C.M. = 20.0 EXCELLENT "T" = 34 VACC C.M. = 4.7 CONT C.M. = 20.0 NONE

TABLE 2 (Cont'd)

CHALLENGE ANTIGEN	TITER RESPONSE NO. >1:8/ TOTAL	PROTECTION
5 FELINE CHLAMYDIA PSITTACI SC	NA	EXCELLENT AV. MS = 0.54
IM	NA	EXCELLENT EXCELLENT AV. M.S. = 0.49
CONT	NA	NONE AV. M.S. = 2.04

C.M. = CUMULATIVE MEAN SCORE

AV. M.S. = AVERAGE MEAN SCORE

10 "T" = A STATISTICAL CALCULATION (one-tailed, Mann Whitney
modification of Wilcoxon's two samples test) COMPARING
THE CLINICAL SCORES OF VACCINATES WITH THOSE
OF CONTROLS (DEFINED BY 9 CFR 115.130, 113.149,
113.131, 115.150, SAM 310 AND SAM 311. A "T" OF ≥31
15 IS EQUIVALENT TO PROTECTION.

As further embodiments of the present invention, the vaccine composition can be administered as sustained release product(s), e.g. formulated with lactide-glycolide copolymer, microparticles which produce sustained release and as an implant.

20 The present invention also provides a method for preventing chlamydia infection in felines comprising administering to a feline an immunogenically effective amount of the vaccine composition described above. The routes of administration of the present invention are parenteral (subcutaneous, intramuscular, intraperitoneal and intradermal)
25 or oral/nasal. The preferred routes of administration are subcutaneous and intramuscular. It has been discovered that an effective regimen of

treatment includes administering the vaccine composition at least about two times with each administration separated by about two to about four weeks, preferably from about fourteen to about thirty days.

The working examples set forth below are intended to illustrate the
5 invention without limiting its scope.

EXAMPLES

Example 1 Monovalent Feline *Chlamydia psittaci*

Cell stock of Buffalo Green Monkey cells were thawed, added to growth medium containing DMEM/H + 5% fetal bovine serum, 10mM
10 HERPES buffer and 30µg/mL of Neomycin and centrifuged for 10 to 15 minutes at 400-600 x g. Centrifuged cell stock was suspended in fresh growth medium and planted into roller bottles. The roller bottles were incubated rotating at 37° C until the cells grew to confluency.

Subcultures of the cells were made until the desired number of roller
15 bottles for production purposes were obtained. Usually production lots vary from 50 to 500 roller bottles. When the production subculture roller bottles of the BGM cells were 3-5 days old and at least 95% confluent, the growth medium was removed and *Chlamydia psittaci* seed was added at a multiplicity of infection (MOI) of 0.01 to 0.1. The medium
20 used for *Chlamydia* growth was DMEM/H plus 30 µg/mL Neomycin. The roller bottles were reincubated for adsorption of the *Chlamydia* at 36-38° C for one hour and then 200 mL more of media was added to each roller bottle. Incubation at 36-38° C was continued for 5-7 days or until CPE was >80%. Roller bottle fluids were harvested by shaking the
25 roller bottles to remove any remaining cells from the surface and transferring the harvest fluids into a container. Harvested fluids were clarified (purified) by filtration through a 5 micron polypropylene filter to remove extraneous cell debris. The clarified fluids were inactivated with 0.01M Binary Ethylenimine (BEI) for 72 hours at 2-8° C. After

inactivation, the BEI was neutralized with Sodium Thiosulfate at a 0.02M final concentration.

The purified, inactivated Chlamydia psittaci was diluted to three different levels of antigen (three different antigenic masses). The highest antigenic mass tested was 100 μ L/dose which was equivalent to approximately 100 μ g/dose, the intermediate antigen mass tested was 50 μ L/dose which was approximately equivalent to 50 μ g/dose while the lowest antigen mass tested was 25 μ L/dose or approximately 25 μ g/dose. All antigenic masses were diluted with phosphate buffered saline so as to q.s. each preparation to 0.95 mL. A volume of 0.05 mL of POLYGEN® was added to each preparation as an adjuvant in order to prepare the final vaccines. One milliliter doses of these vaccines were administered to groups of 5 seronegative cats at a 3 week interval. The first dose was administered on day 0 and the second dose was administered at day 21. A group of 5 seronegative cats, matched in age and environment, were not vaccinated but held as nonvaccinated controls. All cats were challenged both intra-nasally and intra-ocularly with virulent Chlamydia psittaci at 2-8 weeks post booster with the second dose. All cats were monitored daily for 28 days for clinical signs of Chlamydia psittaci disease including temperature, ocular discharge, conjunctivitis, nasal exudate, sneezing, coughing, dyspnea, anorexia, dehydration and depression. A weighted scoring system was used to analyze the data. The more serious signs of disease were given higher numerical values. All data were statistically analyzed in 4-day intervals and are presented in Table 1. These data are graphically presented in Figure 1.

The results presented in Table 1 and Figure 1 clearly demonstrate that the Chlamydia psittaci when prepared according to this invention is efficacious at antigenic masses of as little as 25 μ g/dose. Since this low antigenic mass vaccine conferred protection equivalent to the high antigenic mass vaccine, it is expected that levels below 25 μ g/dose, when

prepared according to the method of the present invention, would also be protective.

Example 2

Inactivated feline Chlamydia psittaci prepared according to
5 EXAMPLE 1 of this invention was mixed with four other inactivated feline
antigens to prepare a multicomponent vaccine. Thirty-five microliters of
POLYGEN® adjuvanted Chlamydia psittaci ($10^{6.0}$ TCID₅₀/mL) were mixed
with feline leukemia at an antigenic dose of 1.25 ELISA relative potency
units/dose adjuvanted with POLYGEN®, $10^{8.0}$ TCID₅₀/dose of
10 POLYGEN® adjuvanted Feline Rhinotracheitis, $10^{7.8}$ TCID₅₀/dose of
POLYGEN® adjuvanted Feline Calicivirus and $10^{5.9}$ TCID₅₀/dose of
POLYGEN® adjuvanted Feline Panleukopenia virus. This 5-way vaccine
was tested for efficacy in vaccination/challenge tests conducted in cats.
At the outset of the experiment, all cats were bled for serum and whole
15 blood samples. Sera were screened for antibody to Feline
Rhinotracheitis, Feline Calicivirus and Feline Panleukopenia virus titers.
All cats started with titers less than 1:2 for those viruses. The cats used
in the FeLV protocol were negative for p27 antigen. Five groups of cats
(n = 74), 13-15 weeks of age, were vaccinated and boosted three
20 weeks later with 1.0 mL of the 5-way vaccine. Approximately ½ of the
cats were vaccinated subcutaneously and ½ were vaccinated
intramuscularly.

Eight vaccinated (4 subcutaneous and 4 intramuscular) cats and
one control cat were evaluated for serological response to Feline
25 Panleukopenia post vaccination and booster. A serological response of
1:8 is considered to be protective for this component. The post
vaccination results are listed in Table 2.

Twelve 5-way vaccinated (6 subcutaneously and 6 intramuscularly)
cats and 4 nonvaccinated control cats were challenged with virulent

Feline Rhinotracheitis virus. Throat swabs and blood samples were taken pre challenge. All cats were monitored for signs of disease post challenge. Clinical disease signs and temperatures were recorded and analyzed with mean scores presented in Table 2. Efficacy is
5 demonstrated by a statistically significant difference in clinical scores between vaccinates and controls.

Twelve 5-way vaccinated (6 subcutaneously and 6 intramuscularly) cats and 4 nonvaccinated control cats were challenged with virulent Feline Calicivirus. Throat swabs and blood samples were taken post
10 challenge. Additionally, cats were monitored for temperature and clinical signs of disease. Clinical signs were recorded, scored and analyzed and are presented in Table 2. Efficacy is demonstrated by a statistically significant difference in clinical scores between vaccinates and controls.

Twenty 5-way vaccinated (10 subcutaneously and 10
15 intramuscularly) cats and 10 nonvaccinated control cats were challenged with virulent Feline Chlamydia psittaci and monitored and scored for clinical signs of disease as described in EXAMPLE 1. Efficacy is demonstrated by a statistically significant difference between vaccinee and control mean scores. Summary results of this challenge are also
20 shown in Table 2.

Twenty-two 5-way vaccinated (11 subcutaneously and 11
intramuscularly) cats and 9 nonvaccinated control cats were challenged with virulent FeLV. This challenge requires that the cats first be immunosuppressed and challenged for 2 consecutive days. Cats were
25 checked from week 3 to week 12 post challenge for viremia by detection of p27 antigen in the blood using an indirect immunofluorescence assay (IFA). Protection was determined using the guidelines as described in Shibley et al. (JAVMA 1991, 199: 1402-1406.) and are presented in Table 2.

It is evident from Table 2 that all 5 components of this multicomponent vaccine comprising the feline Chlamydia psittaci of this invention were efficacious. It should also be noted that none of the vaccinates in this study nor any vaccinates in other studies conducted on
5 the Chlamydia psittaci vaccine or a multicomponent vaccine comprising the Chlamydia psittaci demonstrated local or systemic reactions to the vaccine. The low antigen mass Chlamydia psittaci was the major reason for this lack of reactivity.

While the invention has been described with respect to the above
10 specific embodiments, it should be recognized that various modifications and changes which may be apparent to those skilled in the art to which the invention pertains may be made and also fall within the scope of the invention as defined by the claims that follow:

The claims defining the invention are as follows:

1. An inactivated, immunogenically effective Chlamydia psittaci vaccine which does not produce local and systemic adverse reactions containing
5 less than 50 μg /dose of Chlamydia psittaci.

2. The inactivated, immunogenically effective and non-reactive Chlamydia psittaci vaccine according to Claim 1 which further contains a feline antigen other than the Chlamydia psittaci.

3. The inactivated, immunogenically effective and non-reactive
10 Chlamydia psittaci vaccine according to Claim 2, wherein the other feline antigen is selected from the group consisting of Feline Rhinotracheitis, Feline Caliciyirus, Feline Leukemia virus, Toxoplasma gondii, rabies, Feline Panleukopenia virus, Feline Immunodeficiency virus and Feline Infectious Peritonitis virus.

15 4. A process for preparing a vaccine against chlamydia infections comprising:

- 20
- a) culturing Chlamydia psittaci in egg yolk sac;
 - b) harvesting an egg yolk sac membrane from said egg yolk sac and freezing the harvest as a master seed;
 - c) culturing said master seed or passages of said master seed in a highly susceptible cell line growing on a surface until at least 80% of the cell line is destroyed by the Chlamydia psittaci;
 - d) harvesting the destroyed susceptible cell line and media containing the Chlamydia psittaci accompanying said cell line;
 - e) removing the destroyed cell line from the Chlamydia psittaci;
- 25



- f) inactivating the Chlamydia psittaci;
- g) mixing the inactivated Chlamydia psittaci with an adjuvant and physiologically acceptable carrier.

5. The process of Claim 4, wherein said highly susceptible cell
5 line is a Buffalo Green Monkey cell.

6. The process of Claim 4, wherein said inactivation comprises adding an effective amount of inactivating agent to inactivate Chlamydia psittaci while still retaining its immunogenicity.

7. The process of Claim 6, wherein said inactivating agent is
10 selected from the group consisting of binary ethylenimine, beta-propiolactone, formalin, merthiolate, thimerosal, gluteraldehyde and detergents.

8. The process of Claim 6, wherein the inactivating agent is binary ethylenimine.

15 9. The process of claim 4, wherein the adjuvant is selected from the group consisting of polymers and co-polymers, acrylic acid polymers and co-polymers, polyacrylic acid, surfactants, peptides, oil emulsions, immunomodulators, interferon inducers, ethylene maleic anhydride copolymers and a mixture thereof.

20 10. The process of claim 5, wherein the surfactants are hexadecylamine, saponin, Quil A, aluminium hydroxide or aluminium phosphate, the peptide is muramyl dipeptide, the immunomodulators are interleukins and interferons, and the ethylene maleic anhydride copolymers are EMA 31 or NEOCRYL A640.

25 11. The process of Claim 4, wherein the physiologically acceptable carrier is selected from the group consisting of phosphate buffered saline, saline and minimal essential medium.

30 12. A method for preventing chlamydia infection in felines comprising administering to a feline an immunogenically effective amount of the vaccine of Claim 2.



-17-

13. A method for preventing chlamydia infection in felines comprising administering to a feline an immunogenically effective amount of the vaccine of Claim 4.

14. An inactivated, immunogenically effective Chlamydia psittaci vaccine according to anyone of claims 1-3, processes for its production or methods of treatment involving/containing same, substantially as hereinbefore described with reference to the Examples and the accompanying drawings.

DATED this 31st day of December, 1999

BAYER CORPORATION AND BAYER AG

By its Patent Attorneys

DAVIES COLLISON CAVE







FIG. 1



1/1